How the FDA’s pathway for psychedelics has changed this year.

Illustration: Amelia Kinsinger, Photos: Adobe Stock
After years of stops and starts, pharmaceutical companies and researchers hope the FDA may finally approve a classic psychedelic drug. (And yes, you’ve heard that before.)In order to approve a drug, the FDA decides whether potential benefits outweigh risks, typically based on double-blind randomized controlled clinical trials. There’s debate over how to answer that question for psychedelics and other mind-altering drugs, though.
This year has seen some major progress in advancing FDA guidance and charting a path toward approval, bringing hope that pharma’s multibillion-dollar investment in psychedelics may pay off.
Two years after Lykos Therapeutics (now Resilient Pharmaceuticals) didn’t receive FDA approval for its much-anticipated MDMA treatment, a turbocharged series of updates is giving the psychedelic industry another shot and addressing issues that came up in the original application.
On April 18, President Trump issued an executive order speeding up psychedelic medicine research and development.
Then on April 24, the FDA announced three companies’ drugs would get Commissioner’s National Priority Vouchers (CNPV): London-based Compass Pathways’s COMP360 synthetic psilocybin for treatment-resistant depression, Wisconsin-based Usona Institute’s synthetic psilocybin for major depressive disorder, and New York-based Transcend Therapeutics’s TSND-201, a proprietary formulation of methylone, for PTSD. Transcend was acquired by Otsuka Pharmaceutical’s US subsidiary in June.
All three were already fast-tracked with the breakthrough therapy designation. But the CNPVs, part of a pilot program that began in June 2025, speed up the review process to one or two months compared to over six months under other priority review programs, according to an FDA page last updated Oct. 19. “That’s a shocking acceleration,” Boris Heifets, an associate professor at Stanford University School of Medicine who researches psychiatric treatments including psychedelics, told Healthcare Brew.
On the same day it announced the CNPV recipients, the FDA also announced Miami-based biopharma DemeRx could start conducting the first US human trials of noribogaine for alcohol use disorder. (Ibogaine is a psychoactive substance derived from a shrub native to Central Africa.)
In July, the FDA finalized new recommendations for the industry, about three years after it had published a draft of initial guidance. Several FDA officials subsequently published a paper in the New England Journal of Medicine in September about the agency’s updated guidelines.
These new recommendations address issues that came up in Lykos’s drug application, Jerry Avorn, a professor of medicine at Harvard Medical School, told Healthcare Brew.
FDA reviewers found that Lykos “did not appropriately document” adverse events that the agency had previously required—including euphoria—which would help the agency evaluate potential for abusing the drug. Requested laboratory data on hepatotoxicity was not collected in Phase 3 studies, either.
An FDA briefing document about Lykos’s drug also found MDMA’s obvious effects meant it was “nearly impossible to blind,” meaning participants and administrators could tell if participants got a placebo or not. This made “interpretation of the data…challenging,” the FDA reviewers wrote.
Gerald Busch, a member of trade group the American Psychiatric Association’s Council on Addiction Psychiatry, told Healthcare Brew he believes these drugs have “great potential” but unblinding is a big hurdle.
“Then you have these pressures—like this executive order to hurry things along—and that is a combination of cause for concern,” he said.
White House spokesperson Allison Schuster told Healthcare Brew the executive order “paves the way for more research to inform future decision-making while not compromising safety or lowering any standards for approval.” The FDA and its parent agency, the Department of Health and Human Services, did not respond by deadline.
Heifets said unblinding isn’t just a concern for psychedelics. Psychiatric drugs like SSRIs also create noticeable changes and side effects that may unblind trials.
Dismissing psychedelic study results as uninterpretable for this reason is “an extreme overreaction, I think, to a long-standing issue in the field,” he said.
Heifets said he agrees with the FDA’s July guidance, which says alternatives to a placebo, like a low dose of the drug or a different psychoactive drug that mimics the drug’s effects, could be used.
The July guidance also gave a nonbinding recommendation for researchers to follow participants to see if one or a few doses can provide a long-lasting effect, and noted researchers should document all central nervous system effects, including euphoria.
Another issue is that the FDA does not regulate the practice of medicine. That responsibility falls to the states.
This is an issue for psychedelics because administration “has always been a key part of the psychedelic experience, whether it was the illicit stuff…or the clinical applications in the trials,” said Avorn, who is also the author of Rethinking Medications, a book about the drug development system.
The FDA could, however, require participation in its Risk Evaluation and Mitigation Strategy (REMS) drug safety program as a condition of approval. This program requires pharmaceutical manufacturers to “develop, implement, and assess” a strategy that instructs patients and providers to take special steps to reduce a specific adverse event, per the agency’s FAQ page. The FDA has required REMS for 68 drug products such as Johnson & Johnson’s Spravato (esketamine), approved in 2019 for treatment-resistant depression.
Another FDA decision is anticipated shortly.
Compass announced Nov. 9 that it had completed its submission of a New Drug Application (NDA) to the FDA for COMP360. If the CNPV works as planned, the FDA should decide within one or two months.
News outlet Psychedelic Alpha reported on Nov. 2 that Usona has finished its NDA submission. Resilient Pharmaceuticals refiled in the summer, though named spokespeople for these companies have not confirmed either of those updates on the record and could not be reached for comment. Usona declined to comment.